FDA expands Anktiva approval to high-grade papillary-only BCG-unresponsive bladder cancer
The FDA has expanded Anktiva's approval to include adults with high-grade papillary-only BCG-unresponsive non-muscle invasive bladder cancer, establishing the first approved treatment specifically for this population.
Anktiva (nogapendekin alfa inbakicept-pmln) in combination with bacillus Calmette-Guérin is now authorised for eligible patients with high-grade papillary-only disease, extending its previous indication for carcinoma in situ-associated bladder cancer.
The decision draws on evidence from the QUILT-3.032 development programme and regulatory consideration of related disease presentations, broadening treatment options for patients whose cancer has not responded to BCG.
Field | Content |
Article Type | Approvals |
Drug Name | Anktiva |
Generic Name | Nogapendekin alfa inbakicept-pmln |
Company | ImmunityBio |
Regulatory Authority | U.S. Food and Drug Administration |
Regulatory Decision | Expanded indication approval |
New Indication | BCG-unresponsive non-muscle invasive bladder cancer with high-grade papillary-only tumours |
Patient Population | Adults with high-grade papillary-only BCG-unresponsive NMIBC |
Previously Approved Population | BCG-unresponsive NMIBC with carcinoma in situ |
Treatment Regimen | Anktiva in combination with bacillus Calmette-Guérin (BCG) |
Therapeutic Area | Oncology; bladder cancer |
Therapeutic Modality | IL-15 receptor agonist immunotherapy |
Clinical Evidence | QUILT-3.032 development programme and supporting regulatory evidence |
Approval Significance | First FDA-approved treatment specifically for the high-grade papillary-only BCG-unresponsive NMIBC population |
Geography | United States |
What Happened | The FDA expanded Anktiva's indication to include high-grade papillary-only BCG-unresponsive non-muscle invasive bladder cancer. |
Why It Matters | The decision provides a newly authorised treatment option for a patient population with limited bladder-preserving therapeutic choices. |
Supporting Context | The expanded indication builds on Anktiva's existing authorisation in BCG-unresponsive carcinoma in situ-associated disease. |
Key Takeaway | Anktiva plus BCG is now FDA-approved for eligible adults with high-grade papillary-only BCG-unresponsive NMIBC. |
What to Watch | Clinical guideline updates, physician adoption, reimbursement and longer-term treatment outcomes. |
Primary Source | U.S. Food and Drug Administration |
Relevant Date | 14 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
댓글